share_log

Truist Securities Downgrades TCR2 Therapeutics to Hold, Lowers Price Target to $3

Truist Securities Downgrades TCR2 Therapeutics to Hold, Lowers Price Target to $3

Truist Securities 将TCR2 Therapeutics的评级下调至持有,将目标价
Benzinga ·  2023/03/08 09:45

Truist Securities analyst Asthika Goonewardene downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Hold and lowers the price target from $8 to $3.

Truist证券分析师Asthika Goonewardene将TCR2治疗公司(纳斯达克:TCRR)的评级从买入下调至持有,并将目标价从8美元下调至3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发